Maternal RSV vaccine data reveal uptake disparities
These findings come as many health care professionals still report limited confidence and inconsistent practices regarding RSV immunization discussions.
Food Insecurity and the Dangers of Infant Formula Dilution
Weekly review: Multiple FDA action items, USPSTF recommendation, and more
Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.
Demystifying Infant Formula
FDA approves NVX-CoV2705 COVID-19 vaccine
NVX-CoV2705 is indicated for individuals aged 12 to 64 years with an underlying condition that poses high risk for severe COVID-19 outcomes.
Age, condition-specific risks for severe RSV disease in children
Severe RSV disease in 2022–2023 was most likely to occur in infants under 6 months and older children with pulmonary or neurologic conditions.
